{"product_id":"inositol-for-polycystic-ovary-syndrome-what-a-major-review-of-13-meta-analyses-found","title":"Inositol for Polycystic Ovary Syndrome: What a Major Review of 13 Meta-Analyses Found","description":"\u003cp\u003eAn umbrella review of 13 meta-analyses of randomized controlled trials found that inositol supplements improve several core features of polycystic ovary syndrome (PCOS). Compared with placebo or folic acid, inositol lowered luteinizing hormone, free testosterone, fasting insulin and insulin resistance scores, and it roughly doubled the odds of live birth and ovulation. However, inositol was largely no better than metformin on most measures, and the certainty of the underlying evidence was mostly low or very low, with no outcome rated high quality.\u003c\/p\u003e\n\n\u003ch1\u003eInositol for Polycystic Ovary Syndrome: What a Major Review of 13 Meta-Analyses Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Review\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#quality\"\u003eHow Strong Was the Evidence?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#hormones\"\u003eKey Findings: Hormone Levels\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#glycemic\"\u003eKey Findings: Blood Sugar and Insulin\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#lipids\"\u003eKey Findings: Cholesterol and Triglycerides\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#body\"\u003eKey Findings: Body Measurements\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#reproduction\"\u003eKey Findings: Fertility and Pregnancy\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#subtypes\"\u003eComparing Inositol Types: Myo-Inositol vs. D-Chiro-Inositol\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eWhat These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAn umbrella review of 13 meta-analyses found inositol improved several hormone, metabolic and fertility outcomes in PCOS compared with placebo or folic acid.\u003c\/li\u003e\n\u003cli\u003eMost evidence was low or very low certainty; no outcome was rated high quality, so results need cautious interpretation.\u003c\/li\u003e\n\u003cli\u003eInositol was largely no better than metformin on most measures, except triglycerides and pregnancy rates.\u003c\/li\u003e\n\u003cli\u003eMyo-inositol showed the clearest benefits; D-chiro-inositol alone should be used with caution, and the combination was not consistently better.\u003c\/li\u003e\n\u003cli\u003eInositol did not significantly change BMI; the only significant body-measurement finding was a small waist-to-hip ratio reduction versus placebo or folic acid.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003ePolycystic ovary syndrome (PCOS) is a common hormonal and metabolic disorder. PCOS is marked by persistent failure to ovulate (anovulation), high levels of male-type hormones (hyperandrogenism), and ovaries with many small cysts on ultrasound. The condition is also closely linked to obesity and insulin resistance (when the body's cells respond poorly to insulin).\u003c\/p\u003e\n\n\u003cp\u003ePCOS is widespread and becoming more common. Over the past three decades, both the number of new cases and the total number of people affected have risen significantly. About \u003cstrong\u003e10% to 13% of the global population\u003c\/strong\u003e currently has PCOS, according to the review authors.\u003c\/p\u003e\n\n\u003cp\u003eThe causes of PCOS are multifactorial. Genetic susceptibility, environmental factors, and effects passed between generations all interact. This complexity explains why PCOS produces such a wide range of symptoms, linking metabolic problems, reproductive problems, and psychological challenges.\u003c\/p\u003e\n\n\u003cp\u003eInfertility is a central concern. PCOS is responsible for approximately \u003cstrong\u003e70% of all cases of infertility caused by failure to ovulate\u003c\/strong\u003e. People with PCOS also face a higher lifelong risk of obesity, metabolic syndrome, type 2 diabetes, and coronary artery disease.\u003c\/p\u003e\n\n\u003cp\u003eStandard treatment combines lifestyle changes and medication. For mild symptoms, doctors recommend lifestyle changes first. Drug treatment is chosen according to symptom severity and targets insulin resistance, failure to ovulate, and excess male hormones. The main medications are metformin (MET), clomiphene citrate, and oral contraceptive pills (OCP). Because PCOS is so complex, building a personalized treatment plan remains a significant challenge in clinical practice.\u003c\/p\u003e\n\n\u003cp\u003eNutritional supplements have shown notable clinical benefits in PCOS research. Studies show that taking inositol helps lower insulin resistance and improves metabolic measures in people with PCOS. Inositol works through several biological processes. These include insulin and gonadotropin signaling, energy metabolism, follicle growth, glucose balance, cell movement, and neural tube development. Inositol also plays a critical role in supporting fertility and normal embryonic development.\u003c\/p\u003e\n\n\u003cp\u003eMany meta-analyses have already examined inositol in PCOS. However, no integrated research had comprehensively assessed the strength, consistency, and methodological quality of this evidence across key clinical areas. Those areas include hormone levels, metabolic markers, body measurements, and reproductive outcomes. This umbrella review was designed to fill that gap.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Review\u003c\/h2\u003e\n\n\u003cp\u003eAn umbrella review is a study of studies. It gathers existing meta-analyses (statistical combines of multiple trials) and evaluates the overall body of evidence. This review followed the PRISMA-P guidelines and was registered in PROSPERO, an international register of systematic reviews, under the identifier CRD420251146691.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers searched four databases: PubMed, Scopus, Embase, and Web of Science. The search covered all records from each database's start through August 2025. Search terms related to PCOS included \"Polycystic Ovary Syndrome\" and \"Stein-Leventhal Syndrome.\" Terms related to the supplement included \"Inositol,\" \"Chiro-Inositol,\" and \"Myo Inositol.\" Terms related to study type included \"Meta-Analysis,\" \"meta-analyses,\" \"meta-analyze,\" and \"Systematic Review.\" The researchers applied no language restrictions.\u003c\/p\u003e\n\n\u003cp\u003eTwo researchers screened titles and abstracts independently. They then evaluated full texts and manually checked references against the inclusion criteria. A third researcher resolved disagreements.\u003c\/p\u003e\n\n\u003cp\u003eStudies had to meet the PICOS criteria to be included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePopulation:\u003c\/strong\u003e adult women with PCOS\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInterventions:\u003c\/strong\u003e inositol, including myo-inositol (MI), D-chiro-inositol (DCI), or an MI plus DCI combination\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparators:\u003c\/strong\u003e placebo, no treatment, or any active intervention such as an insulin-sensitizing agent or an ovulation-inducing agent\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOutcomes:\u003c\/strong\u003e hormone and lipid profiles, body measurements, and reproductive outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers excluded several types of studies. These were studies where participants received other interventions, laboratory and animal studies, case reports, observational studies, and quasi-experimental designs. They also excluded reviews without quantitative analysis, systematic reviews without meta-analysis, and studies that failed to provide comprehensive data.\u003c\/p\u003e\n\n\u003cp\u003eTwo researchers extracted data independently, and a third checked all discrepancies against the original materials. The extracted items included first author, publication year, country or region, number of included studies, and sample size. The extracted items also included details of intervention and control groups, study duration, outcome measures, and effect sizes with 95% confidence intervals (CI).\u003c\/p\u003e\n\n\u003cp\u003eTwo validated tools graded the evidence. \u003cstrong\u003eAMSTAR-2\u003c\/strong\u003e (A Measurement Tool to Assess Systematic Reviews, version 2) rated the methodological quality of each meta-analysis. The tool uses a 16-item checklist. The checklist gives particular attention to seven items that flag \"critical flaws.\" Based on these items, each review received a confidence rating. The confidence rating was high, moderate, low, or very low. \u003cstrong\u003eGRADE\u003c\/strong\u003e (Grading of Recommendations, Assessment, Development, and Evaluation) rated the certainty of evidence for every outcome as high, moderate, low, or very low.\u003c\/p\u003e\n\n\u003cp\u003eThis review was a descriptive synthesis rather than a new statistical pooling. All effect sizes came from the original meta-analyses. For continuous outcomes, the researchers reported mean difference (MD) with 95% CI. For categorical outcomes, they reported risk ratio (RR) with 95% CI. All original meta-analyses used random-effects models. Statistical heterogeneity (how much results differed between studies) was measured with the I² statistic and Cochran's Q test. An I² value above 50% indicated large heterogeneity, and a heterogeneity test P value below 0.10 was considered significant. Because fewer than 10 studies were included for each outcome, the researchers did not perform small-study-effects analysis. The analysis used Review Manager version 5.4.\u003c\/p\u003e\n\n\u003ch2 id=\"quality\"\u003eHow Strong Was the Evidence?\u003c\/h2\u003e\n\n\u003cp\u003eThe search identified 334 records from the four databases. After removing 180 duplicates, the researchers excluded 125 studies based on titles and abstracts and 13 more after full-text review. The final set was \u003cstrong\u003e13 meta-analyses published between 2017 and 2022\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe number of randomized controlled trials (RCTs) inside each meta-analysis ranged from 2 to 35. Sample sizes varied widely. For example, one meta-analysis included 35 trials with 4,668 participants, while another included 2 trials with 371 participants. The included reviews came from many countries, including Australia, Italy, Pakistan, Hungary, India, Spain, the UK, New Zealand, Switzerland, and China. Study durations ranged from 3 to 48 weeks.\u003c\/p\u003e\n\n\u003cp\u003eThe methodological quality of the 13 meta-analyses, rated by AMSTAR-2, was modest:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh quality:\u003c\/strong\u003e 23.1% (about 3 in 13)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow quality:\u003c\/strong\u003e 53.8% (about 7 in 13)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVery low quality:\u003c\/strong\u003e 23.1% (about 3 in 13)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe GRADE assessment covered 85 evidence items across all outcomes. It found \u003cstrong\u003eno high-quality evidence at all\u003c\/strong\u003e. Of the 85 items:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eModerate quality:\u003c\/strong\u003e 18.9%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLow quality:\u003c\/strong\u003e 40%\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVery low quality:\u003c\/strong\u003e 41.1%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis means that most findings rest on low or very low certainty evidence. The review authors stress that results based on low-quality evidence require cautious interpretation and should not solely guide clinical decisions.\u003c\/p\u003e\n\n\u003ch2 id=\"hormones\"\u003eKey Findings: Hormone Levels\u003c\/h2\u003e\n\n\u003cp\u003eSeven sex-hormone outcomes were analyzed from six published studies. Compared with placebo or folic acid (FA), inositol significantly improved several hormone measures.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLuteinizing hormone (LH)\u003c\/strong\u003e fell significantly. Two studies found a mean difference of \u003cstrong\u003e-3.43 IU\/L (95% CI: -4.29 to -2.56, P \u0026lt; 0.00001)\u003c\/strong\u003e. There was no heterogeneity between studies (I² = 0%), and the certainty of evidence was low.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFollicle-stimulating hormone (FSH)\u003c\/strong\u003e also fell, with a mean difference of \u003cstrong\u003e-1.24 IU\/L (95% CI: -1.70 to -0.78, P \u0026lt; 0.00001)\u003c\/strong\u003e. Heterogeneity was moderate (I² = 52%), and the certainty of evidence was very low.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTotal testosterone (TT)\u003c\/strong\u003e results were mixed. Across five studies, the overall reduction was small and not statistically significant (MD -0.20 nmol\/L, 95% CI: -0.46 to 0.06, P = 0.14). Heterogeneity was substantial (I² = 61%), which limits how much this overall result can be interpreted. The effect was clearer when inositol was compared with placebo or folic acid (MD -0.62 nmol\/L, 95% CI: -1.12 to -0.11, P = 0.02, I² = 0%). That comparison had moderate-quality evidence. There was no significant difference compared with metformin. For DCI versus placebo or folic acid, total testosterone fell markedly (MD -1.45 nmol\/L, 95% CI: -2.43 to -0.47, P = 0.004, low-quality evidence).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFree testosterone (FT)\u003c\/strong\u003e improved significantly. Four studies found a mean difference of \u003cstrong\u003e-0.02 nmol\/L (95% CI: -0.02 to -0.01, P \u0026lt; 0.00001)\u003c\/strong\u003e, with moderate-quality evidence. DCI versus placebo or folic acid also produced a significant reduction (MD -0.02 nmol\/L, 95% CI: -0.03 to -0.01, P = 0.0002, low-quality evidence). The MI plus DCI combination did not show a statistically significant effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAndrostenedione\u003c\/strong\u003e fell significantly across five studies (pooled MD -1.84 nmol\/L, 95% CI: -3.25 to -0.44, P = 0.01). However, heterogeneity was very high (I² = 85%), so this result needs cautious interpretation. The effect was clearer in the placebo or folic acid subgroup (MD -2.67 nmol\/L, 95% CI: -3.68 to -1.66, P \u0026lt; 0.00001, moderate-quality evidence). There was no significant difference compared with metformin. In the DCI versus placebo or folic acid subgroup, androstenedione fell markedly (MD -1.81 nmol\/L, 95% CI: -3.63 to -0.00, P = 0.05, low-quality evidence). The MI plus DCI combination was not statistically significant.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSex hormone-binding globulin (SHBG)\u003c\/strong\u003e, a protein that binds sex hormones in the blood, rose significantly across six studies (overall MD 17.57 nmol\/L, 95% CI: 5.53 to 29.61, P = 0.004). Heterogeneity was very high (I² = 91%). The placebo or folic acid subgroup showed a clearer effect with no heterogeneity (MD \u003cstrong\u003e36.72 nmol\/L, 95% CI: 28.52 to 44.91, P \u0026lt; 0.00001, I² = 0%\u003c\/strong\u003e, moderate-quality evidence). There was no significant difference compared with metformin. The DCI versus placebo or folic acid subgroup also showed a significant increase (MD 55.45 nmol\/L, 95% CI: 25.99 to 84.91, P = 0.0002, low-quality evidence). The MI plus DCI combination showed no statistically significant effect.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDehydroepiandrosterone sulfate (DHEAS)\u003c\/strong\u003e, another androgen hormone, fell significantly compared with placebo or folic acid across three studies (MD -3.58 µmol\/L, 95% CI: -3.99 to -3.17, P \u0026lt; 0.00001, I² = 0%, moderate-quality evidence). There was no significant difference overall or compared with metformin. The DCI versus placebo or folic acid subgroup also showed a significant decrease (MD -4.57 µmol\/L, 95% CI: -7.63 to -1.51, P = 0.003, low-quality evidence). The MI plus DCI combination did not produce statistically significant results.\u003c\/p\u003e\n\n\u003ch2 id=\"glycemic\"\u003eKey Findings: Blood Sugar and Insulin\u003c\/h2\u003e\n\n\u003cp\u003eFive measures of blood sugar and insulin were extracted: fasting glucose (FG), fasting insulin (FI), and the homeostatic model assessment of insulin resistance (HOMA-IR, a calculated score of insulin resistance). The five measures also included area under the curve (AUC) for glucose and AUC for insulin.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFasting insulin\u003c\/strong\u003e fell significantly across six studies (overall MD -10.92 pmol\/L, 95% CI: -17.69 to -4.16, P = 0.002). Heterogeneity was very high (I² = 93%). The reduction was stronger versus placebo or folic acid (MD \u003cstrong\u003e-23.40 pmol\/L, 95% CI: -32.80 to -14.01, P \u0026lt; 0.00001\u003c\/strong\u003e, low-quality evidence). There was no significant difference in the metformin subgroup.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHOMA-IR\u003c\/strong\u003e improved significantly across seven studies (overall MD -0.51, 95% CI: -0.88 to -0.14, P = 0.007). Heterogeneity was again very high (I² = 93%). The subgroup compared with placebo or folic acid showed a significant effect with less heterogeneity (MD \u003cstrong\u003e-1.09, 95% CI: -1.35 to -0.83, P \u0026lt; 0.00001, I² = 40%\u003c\/strong\u003e, moderate-quality evidence). No significant effect appeared in the metformin subgroup.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAUC insulin\u003c\/strong\u003e fell significantly overall in two studies (MD -16,212.32, 95% CI: -23,800.77 to -8,623.87, P \u0026lt; 0.0001). Heterogeneity was moderate (I² = 66%), and the certainty of evidence was very low. The placebo or folic acid subgroup also showed a significant reduction (MD -17,571.05, 95% CI: -24,229.85 to -10,912.25, P \u0026lt; 0.00001), again with very low-quality evidence and considerable heterogeneity. There was no significant difference in the MI versus metformin subgroup or the DCI versus placebo or folic acid subgroup.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFasting glucose and AUC glucose did not improve significantly\u003c\/strong\u003e with inositol treatment in any analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"lipids\"\u003eKey Findings: Cholesterol and Triglycerides\u003c\/h2\u003e\n\n\u003cp\u003eOnly two studies reported lipid parameters: cholesterol, triglycerides, high-density lipoprotein (HDL, the \"good\" cholesterol), and low-density lipoprotein (LDL, the \"bad\" cholesterol). Because one study used placebo or folic acid as the control and the other used metformin, the researchers ran separate subgroup analyses for each parameter.\u003c\/p\u003e\n\n\u003cp\u003eInositol did not significantly raise HDL or LDL levels in any comparison. For total cholesterol, a significant effect appeared only in the subgroup comparing inositol with placebo or folic acid (MD 0.56, 95% CI: 0.04 to 1.08, P = 0.03, low-quality evidence). Neither the overall pooled estimate nor the comparison with metformin showed a statistically significant effect.\u003c\/p\u003e\n\n\u003cp\u003eFor triglycerides, the overall pooled effect was not significant. However, both subgroup analyses showed significant reductions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInositol versus placebo or folic acid: MD -0.36 (95% CI: -0.69 to -0.02, P = 0.04, low-quality evidence)\u003c\/li\u003e\n\u003cli\u003eMI or MI plus folic acid versus metformin: MD -0.06 (95% CI: -0.09 to -0.02, P = 0.001, low-quality evidence)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"body\"\u003eKey Findings: Body Measurements\u003c\/h2\u003e\n\n\u003cp\u003eTwo body measurements were evaluated: body mass index (BMI) and waist-to-hip ratio (WHR). Five studies reported BMI, and two studies reported WHR.\u003c\/p\u003e\n\n\u003cp\u003eOnly one result was statistically significant: the waist-to-hip ratio in the subgroup comparing inositol with placebo or folic acid (MD -0.02, 95% CI: -0.03 to -0.01, P \u0026lt; 0.0001, low-quality evidence). Inositol did not significantly change BMI in any analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"reproduction\"\u003eKey Findings: Fertility and Pregnancy\u003c\/h2\u003e\n\n\u003cp\u003eReproductive outcomes included pregnancy rates or clinical pregnancy, live births, and ovulation rate. These are the outcomes many patients care about most, and the results were encouraging.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePregnancy rates or clinical pregnancy\u003c\/strong\u003e were analyzed from six studies across six subgroups. Inositol significantly increased pregnancy rates overall and in the comparisons with placebo or folic acid, with metformin, and with DCI. The MI plus DCI combination was significantly superior to placebo. No significant differences appeared in the remaining subgroups. The specific results were:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOverall:\u003c\/strong\u003e RR 1.29 (95% CI: 1.11 to 1.50, P = 0.001), moderate-quality evidence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInositol versus placebo or folic acid:\u003c\/strong\u003e RR 1.31 (95% CI: 1.05 to 1.63, P = 0.02), moderate-quality evidence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInositol versus metformin:\u003c\/strong\u003e RR 1.43 (95% CI: 1.14 to 1.79, P = 0.002), moderate-quality evidence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMI versus DCI:\u003c\/strong\u003e RR 2.86 (95% CI: 1.14 to 7.17, P = 0.03), moderate-quality evidence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMI plus DCI versus placebo or folic acid:\u003c\/strong\u003e RR 1.45 (95% CI: 1.06 to 1.98, P = 0.02), low-quality evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLive births\u003c\/strong\u003e were analyzed from two studies, one of which included both a placebo or folic acid group and a metformin group. Only the inositol versus placebo or folic acid subgroup showed a significant increase in live birth rate: \u003cstrong\u003eRR 2.29 (95% CI: 1.07 to 4.93, P = 0.03)\u003c\/strong\u003e. This result was based on limited studies and low-quality evidence. No significant differences appeared overall or in the metformin subgroup.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOvulation rate\u003c\/strong\u003e improved significantly. The risk ratio was \u003cstrong\u003e2.75 (95% CI: 1.71 to 4.41, P \u0026lt; 0.0001)\u003c\/strong\u003e. Against placebo or folic acid the ovulation risk ratio was 2.75, while across all control groups the overall risk ratio was 1.36 (95% CI: 1.04 to 1.77, low-quality evidence).\u003c\/p\u003e\n\n\u003ch2 id=\"subtypes\"\u003eComparing Inositol Types: Myo-Inositol vs. D-Chiro-Inositol\u003c\/h2\u003e\n\n\u003cp\u003eThe review compared different forms of inositol across subgroups. The findings suggest that the type of inositol matters for which outcomes improve.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMyo-inositol (MI), alone or with folic acid,\u003c\/strong\u003e was superior for metabolic and reproductive outcomes. Compared with placebo, folic acid or no treatment, it significantly lowered free testosterone and the area under the curve for insulin, and its pregnancy rates were higher than with metformin and with D-chiro-inositol.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eD-chiro-inositol (DCI) alone\u003c\/strong\u003e showed significant effects on some hormone measures, including total testosterone, free testosterone, androstenedione, SHBG, and DHEAS. However, the review authors state that DCI monotherapy (used alone) should be used with caution in clinical practice.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCombination therapy (MI plus DCI)\u003c\/strong\u003e did not consistently outperform the single forms. The combination showed a significant benefit only for pregnancy rates compared with placebo.\u003c\/p\u003e\n\n\u003cp\u003eThe review authors conclude that these differences between inositol subtypes may inform personalized treatment. In other words, the choice of inositol form could eventually be matched to each patient's main problem, whether that is insulin resistance, excess male hormones, or difficulty conceiving.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat These Findings Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eInositol improves core manifestations of PCOS. The review found benefits across hormones, insulin resistance, blood fats, and fertility. The strongest and most consistent findings, supported by moderate-quality evidence, were for total testosterone, free testosterone, sex hormone-binding globulin, HOMA-IR, and pregnancy and ovulation rates.\u003c\/p\u003e\n\n\u003cp\u003eThese results make inositol a promising therapy for PCOS. It is a nutritional supplement rather than a prescription drug, and the review found a meaningful effect on several outcomes that matter to patients.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the comparison with metformin is important. Against metformin, inositol's effects on most parameters were not significant. The exceptions were triglycerides and pregnancy rates. This means inositol should not automatically be seen as a replacement for metformin, which remains a standard insulin-sensitizing medication for PCOS.\u003c\/p\u003e\n\n\u003cp\u003eThe review also highlights that the quality of evidence varies widely by outcome. A moderate GRADE rating means researchers are moderately confident in the result. A low or very low rating means the true effect may be substantially different from the estimate. Patients and clinicians should weigh this when interpreting any single finding.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe most important limitation is the certainty of the evidence. Of 85 evidence items, none were rated high quality. Only 18.9% were moderate, while 40% were low and 41.1% were very low. The review authors state clearly that outcomes based on low-quality evidence require cautious interpretation and should not solely guide clinical decisions.\u003c\/p\u003e\n\n\u003cp\u003eMany pooled results had substantial heterogeneity. High I² values mean the individual studies produced quite different results. This was true for total testosterone, androstenedione, SHBG, fasting insulin, HOMA-IR, and AUC insulin. When studies disagree this much, the combined estimate is less reliable.\u003c\/p\u003e\n\n\u003cp\u003eThe number of underlying studies was often small. Some outcomes, such as live births, lipid levels, and waist-to-hip ratio, rested on only two studies. The review could not perform small-study-effects analysis because fewer than 10 studies were available for each outcome. This means the researchers could not check whether small studies with extreme results were skewing the findings.\u003c\/p\u003e\n\n\u003cp\u003eThe included meta-analyses were published between 2017 and 2022, and the trials inside them varied widely in duration, from 3 to 48 weeks. The review could not determine long-term effects of inositol on PCOS. The review authors call for larger, rigorous trials to strengthen the evidence base.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, patients with PCOS and their clinicians can consider the following points:\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiscuss inositol as an option, but weigh the evidence.\u003c\/strong\u003e Inositol improved several hormone, metabolic, and fertility outcomes compared with placebo or folic acid. However, most of this evidence is low or very low certainty.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDo not stop prescribed metformin without medical advice.\u003c\/strong\u003e Inositol was largely no better than metformin on most measures. The exceptions were triglycerides and pregnancy rates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk about the inositol type.\u003c\/strong\u003e Myo-inositol, alone or with folic acid, showed the clearest benefits for metabolic and reproductive outcomes. D-chiro-inositol used alone should be used with caution, according to the review authors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDo not expect the combination to be automatically better.\u003c\/strong\u003e MI plus DCI combination therapy did not consistently outperform the single forms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSet realistic expectations about body weight.\u003c\/strong\u003e Inositol did not significantly change BMI in this review. The only significant body-measurement finding was a small reduction in waist-to-hip ratio versus placebo or folic acid.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTrack fertility outcomes with your care team.\u003c\/strong\u003e The largest relative benefits were for ovulation rate (RR 2.75) and live births versus placebo or folic acid (RR 2.29). Both figures come from a limited number of studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAsk for personalized guidance.\u003c\/strong\u003e The review authors suggest that differences between inositol subtypes may support personalized treatment. Your clinician can help match the approach to your main symptoms.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eDoes inositol help with polycystic ovary syndrome (PCOS)?\u003c\/h3\u003e\n\u003cp\u003eAn umbrella review of 13 meta-analyses found inositol improved several PCOS features compared with placebo or folic acid, including luteinizing hormone, free testosterone, fasting insulin and insulin resistance scores. It roughly doubled the odds of live birth and ovulation. However, most evidence was low or very low certainty, and inositol was largely no better than metformin on most measures.\u003c\/p\u003e\n\u003ch3\u003eHow strong is the evidence that inositol works for PCOS?\u003c\/h3\u003e\n\u003cp\u003eThe evidence is mostly low or very low certainty. Of 85 evidence items graded, none were high quality, about 19% were moderate, 40% low and 41% very low. The review authors stress that results based on low-quality evidence require cautious interpretation and should not solely guide clinical decisions.\u003c\/p\u003e\n\u003ch3\u003eIs inositol as good as metformin for PCOS?\u003c\/h3\u003e\n\u003cp\u003eInositol was largely no better than metformin on most measures. The exceptions were triglycerides and pregnancy rates, where inositol showed some advantage.\u003c\/p\u003e\n\u003ch3\u003eWhich type of inositol is most appropriate for PCOS?\u003c\/h3\u003e\n\u003cp\u003eMyo-inositol, alone or with folic acid, was described by the review authors as superior for metabolic and reproductive outcomes; in the subgroup results it significantly lowered free testosterone and insulin area under the curve compared with placebo, folic acid or no treatment, and raised pregnancy rates compared with metformin and D-chiro-inositol. D-chiro-inositol alone showed effects on some hormone measures but should be used with caution, according to the review authors. The combination did not consistently outperform single forms.\u003c\/p\u003e\n\u003ch3\u003eCan inositol help me get pregnant with PCOS?\u003c\/h3\u003e\n\u003cp\u003eIn a review of six studies, inositol increased pregnancy rates overall (risk ratio 1.29) and in several comparisons. Live birth rate was higher versus placebo or folic acid (risk ratio 2.29) in two studies, and ovulation rate improved (risk ratio 2.75). These fertility findings were based on limited studies and low-quality evidence.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of the evidence on inositol for PCOS?\u003c\/h3\u003e\n\u003cp\u003eThe review could not determine long-term effects because trials lasted 3 to 48 weeks. Many results had substantial heterogeneity, meaning studies disagreed. Some outcomes, such as live births and lipid levels, rested on only two studies. The researchers could not check for small-study effects and call for larger, rigorous trials.\u003c\/p\u003e\n\u003ch3\u003eIf I have PCOS and my doctor prescribed metformin, when should I get a second opinion about adding or switching to inositol?\u003c\/h3\u003e\n\u003cp\u003eA second opinion can help when you are weighing inositol against metformin. Inositol was largely no better than metformin on most measures, with exceptions for triglycerides and pregnancy rates, and most supporting evidence is low or very low certainty. The choice of inositol type also matters: myo-inositol showed clearer benefits for metabolic and reproductive outcomes, while D-chiro-inositol alone warrants caution. Do not stop prescribed metformin without medical advice. An independent review of your records can clarify whether inositol fits your main symptoms. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Duan M, Yang M, Li C, Wu X, Yin X, Zhu H.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China; Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Endocrinology, volume 17, article 1741509\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Received 7 November 2025; revised 21 January 2026; accepted 23 January 2026; published 11 February 2026\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fendo.2026.1741509\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystematic review registration:\u003c\/strong\u003e PROSPERO, identifier CRD420251146691\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding and access:\u003c\/strong\u003e Published as an open-access article under the Creative Commons Attribution License (CC BY).\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It restructures one published umbrella review for a general audience. It does not replace advice from your own healthcare provider.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":48074015703196,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ar\/products\/inositol-for-polycystic-ovary-syndrome-what-a-major-review-of-13-meta-analyses-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}